News Focus
News Focus
icon url

La Flaca

10/03/25 11:54 AM

#502083 RE: boi568 #502081

WRONG - the practice is to rely on the most recent FDA draft guidances. You would be correct if the existing guidance for this particular disease were a FINAL guidance. But it was a draft guidance.
icon url

ohsaycanyousee82

10/03/25 12:04 PM

#502086 RE: boi568 #502081

The US Supreme Court is repeatedly proving your accusations to be nonsense.
icon url

sab63090

10/03/25 12:04 PM

#502087 RE: boi568 #502081

boi
I just wish you had more confidence in Dr. Makary....

I like the way he thinks about the problems the old FDA had, hope he is a positive figure and gets recognition for transparency
icon url

Hoskuld

10/03/25 12:10 PM

#502093 RE: boi568 #502081

I don't understand how EMA could require FDA to do...anything?
icon url

Hoskuld

10/03/25 12:31 PM

#502101 RE: boi568 #502081

OK, well we are not going to agree. But, the FDA is more than capable of (ie, in no way prohibited from) approving blarcasemine for AD, should they ever actually submit an NDA.
icon url

rayovac812

10/03/25 12:49 PM

#502110 RE: boi568 #502081

All someone needs to do is find a case where draft guidence was used, over-riding final draft guidance. If this can be found, then it would be procedural, and satisfactorily demonstrate that draft guidance is the rule.